Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Fresenius Kabi Reveals €800m Biopharma Ambitions By 2026

German Firm Also Raises Its Revenue, Margin Guidance For 2023

14 Jun 2023

• By Dean Rudge

Ambition concept with businessman climbing stairs — • Source: Shutterstock

Related Content

Fresenius Pushes Kabi Even Higher As Former Sandoz Exec Named CEO

28 Feb 2023

Fresenius Brings In Transparency Change For Kabi Unit

18 May 2023

Mabxience Sets Out Investment Plans Under Fresenius Ownership

11 Apr 2023

Related Companies

Fresenius Kabi AG

Additional Topics

International Biosimilars Strategy Supply Chain Manufacturing Sales & Earnings BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.